Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
iuvo bioscience is a premier, full-service preclinical contract research organization (CRO) providing expert advisory and proficient laboratory services for the pharmaceutical, biotechnology, and medical device industries. They specialize in supporting product development from discovery through regulatory submission, with core expertise in ophthalmology, dermatology, general toxicology, pharmacology, and biocompatibility testing for medical devices. iuvo bioscience is known for its scientific rigor, client-centric approach, and commitment to advancing human and animal health. In August 2023, iuvo bioscience was acquired by BioIVT, a leading global provider of research models and services.
The Rush, NY facility serves as the central hub for iuvo bioscience's preclinical research operations, including in vivo and in vitro studies, analytical services, project management, and corporate administration.
State-of-the-art laboratory facilities equipped for specialized preclinical research, including vivarium for animal studies, surgical suites, histology, pathology, and bioanalytical labs. Designed to meet GLP (Good Laboratory Practice) standards.
The work culture at iuvo bioscience emphasizes scientific excellence, collaboration, meticulous attention to detail, and a strong commitment to client success and ethical research practices. Employees often highlight the supportive team environment and opportunities for professional growth in a specialized scientific field.
This facility is significant as it houses the core scientific expertise and operational capabilities that enable iuvo bioscience to deliver comprehensive preclinical testing services, particularly in their niche areas of ophthalmology and dermatology.
While iuvo bioscience's primary laboratory operations are centralized in Rush, NY, they serve a global clientele, including pharmaceutical, biotech, and medical device companies across North America, Europe, and Asia. Through its parent company, BioIVT, iuvo bioscience now has an expanded global reach and access to a wider network of resources and facilities worldwide, supporting international research programs and regulatory submissions.
7000 West Henrietta Road
Rush
NY
USA
Address: 1450 Broadway, New York, NY 10018, USA (BioIVT Corporate Office - an example, actual HQ of BioIVT is Westbury)
BioIVT's headquarters and other sites provide a broader network for research models, services, and market access, complementing iuvo's specialized preclinical capabilities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, iuvo BioScience' leadership includes:
iuvo BioScience has been backed by several prominent investors over the years, including:
The most significant change in the last 12 months was the acquisition of iuvo bioscience by BioIVT in August 2023. While specific executive transitions post-acquisition are not widely publicized, such events often lead to integration of leadership. No other major distinct executive hires or departures at iuvo bioscience have been prominently announced outside of this acquisition context.
Discover the tools iuvo BioScience uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
iuvo bioscience, now part of BioIVT, likely uses email formats common in professional organizations. While specific internal patterns may vary, a common format is often first initial followed by last name, or first name.lastname.
Likely [first_initial][last]@iuvo.com (e.g., jdoe@iuvo.com) or [first].[last]@iuvo.com (e.g. jane.doe@iuvo.com). Post-acquisition, emails may transition to @bioivt.com domain.
Format
bburton@iuvo.com (example based on common format for Ben Burton)
Example
70%
Success rate
BioIVT • August 1, 2023
BioIVT announced its acquisition of iuvo bioscience, expanding BioIVT's capabilities in preclinical drug discovery and development, particularly in ophthalmology. The acquisition aims to enhance BioIVT’s portfolio of research models and services....more
Business Wire • January 18, 2022
iuvo bioscience announced the expansion of its ocular biocompatibility testing services for medical devices, further solidifying its expertise in ophthalmic research and development support....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including iuvo BioScience, are just a search away.